

## Review Form 1.6

Journal Name:	<a href="#">Journal of Pharmaceutical Research International</a>
Manuscript Number:	Ms_JPRI_78932
Title of the Manuscript:	A Review on role of shaman chikitsa in the Medorogaw.s.r to dyslipidemia
Type of the Article	Review Article

### **General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

<https://www.journaljpri.com/index.php/JPRI/editorial-policy>

### **PART 1: Review Comments**

	<b>Reviewer's comment</b>	<b>Author's comment</b> (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Compulsory</b> REVISION comments	Methods are completely unsatisfactory and inadequate in detail to ensure a good literature review has been undertaken and no bias has been introduced. No measures of significance are offered to the reader and studies cannot be in anyway compared to produce a meaningful meta-analysis of results. There is systemic bias here.	
<b>Minor</b> REVISION comments	The introduction is littered with incorrect statements i.e. lipids do not allow for absorption of nutrients. Dyslipidaemia is polygenic disorder with environmental and inherited factors.	
<b>Optional/General</b> comments	Due to the use of Ayurveda medical terms the text is incomprehensible and there can be little assessment of biological plausibility. For a pharmacological journal this offers no insight into how supposed herbal medicines work. I think you need to consider re-writing all the text as you are simply contrasting and comparing ayurvedan terms with little meaning translated in the context of their meaningful prescription or efficacy when compared to the the universally accepted pharmaceuticals for hyperlipidaemia e.g. statins or fibrates. I struggle to see how this changes or informs practice.	

### **PART 2:**

	<b>Reviewer's comment</b>	<b>Author's comment</b> (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Are there ethical issues in this manuscript?</b>	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

**Review Form 1.6**

**Reviewer Details:**

Name:	<b>Dominic Worku</b>
Department, University & Country	<b>Swansea University Health board, United Kingdom</b>